Artivion Inc., a leading company in cardiac and vascular surgery, has announced its entry into privately negotiated exchange agreements with certain holders of its 4.250% Convertible Senior Notes due 2025. The company plans to repurchase approximately $95 million in principal amount of these notes in exchange for shares of its common stock. The exact number of shares will be determined based on the trading price of the stock over a four-day period starting May 15, 2025. At the closing stock price of $28.91, this would translate to approximately 4.1 million shares. Additionally, Artivion will pay cash for accrued and unpaid interest to the note holders. The transaction is expected to close around May 28, 2025, pending customary conditions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。